Download PDF
Horm Metab Res 1992; 24(1): 1-4
DOI: 10.1055/s-2007-1003240
Originals

© Georg Thieme Verlag, Stuttgart · New York

Immunotherapy with Ciamexon in the Non Obese Diabetic (NOD) Mouse

J. Krug1 , 4 , E. F. Lampeter1 , A. J. K. Williams1 , E. Procaccini3 , C. Cartledge2 , A. Signore3 , P. E. Beales1 , P. Pozzilli1 , 3
  • 1Department of Diabetes and Metabolism, St. Bartholomew's Hospital, United Kingdom
  • 2Department of Chemical Pathology, St. Bartholomew's Hospital, London, United Kingdom
  • 3Cattedra Endocrinologia (I), Clinica Medica II, University of Rome “La Sapienza”, Rome, Italy
  • 4Stadtkrankenhaus Leipzig, Leipzig, Germany
Further Information

Publication History

1990

1991

Publication Date:
14 March 2008 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Ciamexon (CMX), a new immunomodulatory compound acting mainly on B-lymphocytes was given orally to 42 NOD mice divided into three sex and litter matched groups (A: 0.3 mg/mouse/day CMX, B: 1.5 mg/mouse/day CMX, C: control) from 7 weeks of age. Animals were followed up for evaluation of diabetes incidence up to 32 weeks of age. There was a tendency for a delayed onset of hyperglycemia in mice of group B up to 26 weeks of age; however no significant difference in the cumulative incidence of diabetes at 32 weeks of age was observed (A: 57.5%, B: 38.5%, C: 38.5%). No differences were found in the number of infiltrated islets in animals culled at 10 weeks of age treated with CMX from 4 weeks of age.

We conclude that CMX does not modify the course of insulitis and diabetes incidence in NOD mice although the appearance of glycosuria was delayed by this treatment.

Key words

NOD Mouse - Type 1 Diabetes - Immunotherapy of Type 1 Diabetes - Ciamexone